These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 27853177

  • 1. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study.
    Janson C, Lööf T, Telg G, Stratelis G, Nilsson F.
    NPJ Prim Care Respir Med; 2016 Nov 17; 26():16053. PubMed ID: 27853177
    [Abstract] [Full Text] [Related]

  • 2. Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler.
    Lähelmä S, Sairanen U, Haikarainen J, Korhonen J, Vahteristo M, Fuhr R, Kirjavainen M.
    J Aerosol Med Pulm Drug Deliv; 2015 Dec 17; 28(6):462-73. PubMed ID: 25757188
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.
    Cazzola M, Ora J, Di Paolo A, Puxeddu E, Calzetta L, Rogliani P.
    Pulm Pharmacol Ther; 2016 Aug 17; 39():48-53. PubMed ID: 27344046
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
    Chrystyn H, Safioti G, Keegstra JR, Gopalan G.
    Int J Pharm; 2015 Aug 01; 491(1-2):268-76. PubMed ID: 26043823
    [Abstract] [Full Text] [Related]

  • 10. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
    Bagherisadeghi G, Chrystyn H, Abadelah M, Larhrib EH.
    Eur J Pharm Sci; 2019 Nov 01; 139():105059. PubMed ID: 31472254
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study.
    Price DB, Thomas V, Richard Dekhuijzen PN, Bosnic-Anticevich S, Roche N, Lavorini F, Raju P, Freeman D, Nicholls C, Small IR, Sims E, Safioti G, Canvin J, Chrystyn H.
    BMC Pulm Med; 2018 Jun 28; 18(1):107. PubMed ID: 29954359
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax® compared to budesonide-formoterol Turbuhaler® in adults and adolescents with persistent asthma.
    Virchow JC, Rodriguez-Roisin R, Papi A, Shah TP, Gopalan G.
    BMC Pulm Med; 2016 Mar 17; 16():42. PubMed ID: 26987997
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.
    Voorham J, Roche N, Benhaddi H, van der Tol M, Carter V, van Boven JFM, Bjermer L, Miravitlles M, Price DB.
    BMJ Open; 2018 Oct 27; 8(10):e022051. PubMed ID: 30368448
    [Abstract] [Full Text] [Related]

  • 15. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method.
    Lähelmä S, Kirjavainen M, Kela M, Herttuainen J, Vahteristo M, Silvasti M, Ranki-Pesonen M.
    Br J Clin Pharmacol; 2005 Feb 27; 59(2):167-73. PubMed ID: 15676038
    [Abstract] [Full Text] [Related]

  • 16. Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions.
    Canonica GW, Arp J, Keegstra JR, Chrystyn H.
    J Aerosol Med Pulm Drug Deliv; 2015 Oct 27; 28(5):309-19. PubMed ID: 26352860
    [Abstract] [Full Text] [Related]

  • 17. Consistent Dosing Through the Salmeterol-Fluticasone Propionate Easyhaler for the Management of Asthma and Chronic Obstructive Pulmonary Disease: Robustness Analysis Across the Easyhaler Lifetime.
    Turpeinen A, Eriksson P, Happonen A, Husman-Piirainen J, Haikarainen J.
    J Aerosol Med Pulm Drug Deliv; 2021 Jun 27; 34(3):189-196. PubMed ID: 32960127
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®).
    Malmberg LP, Everard ML, Haikarainen J, Lähelmä S.
    J Aerosol Med Pulm Drug Deliv; 2014 Oct 27; 27(5):329-40. PubMed ID: 24978441
    [Abstract] [Full Text] [Related]

  • 19. Comparison of two budesonide powder inhalers, Easyhaler and Turbuhaler, in steroid-naïve asthmatic patients.
    Schweisfurth H, Malinen A, Koskela T, Toivanen P, Ranki-Pesonen M, German Study Group.
    Respir Med; 2002 Aug 27; 96(8):599-606. PubMed ID: 12195841
    [Abstract] [Full Text] [Related]

  • 20. Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD.
    De Simón Gutiérrez R, Castro RP.
    Curr Allergy Asthma Rep; 2022 Nov 27; 22(11):151-161. PubMed ID: 36087251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.